| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30082247 | HIV | ENSG00000104267.10 | protein_coding | CA2 | No | No | 760 | P00918 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CA2 |
|---|---|
| DrugBank ID | DB03904 |
| Drug Name | Urea |
| Target ID | BE0000322 |
| UniProt ID | P00918 |
| Regulation Type | |
| PubMed IDs | 20005709; 27789330; 28705076 |
| Citations | Temperini C, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. X-ray crystal studies of the carbonic anhydrase II-trithiocarbonate adduct--an inhibitor mimicking the sulfonamide and urea binding to the enzyme. Bioorg Med Chem Lett. 2010 Jan 15;20(2):474-8. doi: 10.1016/j.bmcl.2009.11.124. Epub 2009 Nov 27.@@Wahiduzzaman, Dar MA, Haque MA, Idrees D, Hassan MI, Islam A, Ahmad F: Characterization of folding intermediates during urea-induced denaturation of human carbonic anhydrase II. Int J Biol Macromol. 2017 Feb;95:881-887. doi: 10.1016/j.ijbiomac.2016.10.073. Epub 2016 Oct 24.@@Prakash A, Dixit G, Meena NK, Singh R, Vishwakarma P, Mishra S, Lynn AM: Elucidation of stable intermediates in urea-induced unfolding pathway of human carbonic anhydrase IX. J Biomol Struct Dyn. 2018 Jul;36(9):2391-2406. doi: 10.1080/07391102.2017.1355847. Epub 2017 Jul 28. |
| Groups | Approved; Investigational |
| Direct Classification | Ureas |
| SMILES | NC(N)=O |
| Pathways | Citrullinemia Type I; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Metolazone Action Pathway; Bumetanide Action Pathway; D-Arginine and D-Ornithine Metabolism; Hyperornithinemia with Gyrate Atrophy (HOGA); Polythiazide Action Pathway; Trichlormethiazide Action Pathway; Hyperprolinemia Type II; Hartnup Disorder; Argininosuccinic Aciduria; L-Arginine:Glycine Amidinotransferase Deficiency; Indapamide Action Pathway; Torsemide Action Pathway; Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency); Hydrochlorothiazide Action Pathway; Triamterene Action Pathway; Lysinuric Protein Intolerance; Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency; Carbamoyl Phosphate Synthetase Deficiency; Eplerenone Action Pathway; Hyperprolinemia Type I; Glucose Transporter Defect (SGLT2); Arginine and Proline Metabolism; Methyclothiazide Action Pathway; Cystinuria; Spironolactone Action Pathway; Blue Diaper Syndrome; Furosemide Action Pathway; Quinethazone Action Pathway |
| PharmGKB | PA451831 |
| ChEMBL | CHEMBL985 |
